Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes

• DOI: 10.1507/endocrj.ej17-0440
• Publication Date: 2018-02-19T22:19:41Z
• Authors: Kei Sawada; Shigehiro Karashima; Mitsuhiro Kometani; Rie Oka; Yoshimichi Takeda; Toshitaka Sawamura; Aya Fujimoto; Masashi Demura; Ayako Wakayama; Mikiya Usukura; Kunimasa Yagi; Yoshiyu Takeda; Takashi Yoneda
• Keywords: Adult; Aged, 80 and over; Glycated Hemoglobin; Male; 2. Zero hunger; Sleep Apnea, Obstructive; Body Weight; Middle Aged; Body Mass Index; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Female; Sodium-Glucose Transporter 2 Inhibitors; Aged; Retrospective Studies

Obstructive sleep apnea syndrome (OSAS) is often associated with metabolic disorders such as obesity and type 2 diabetes may contribute to cardiovascular events. A novel class of antidiabetic drugs, the sodium glucose cotransporter inhibitors (SGLT2i) reduce body weight (BW), although there limited data on their impact OSAS. We therefore evaluated effect SGLT2i OSAS in patients diabetes. The presented study was a retrospective design 18 (4 males, age range 39-81 yr) administrated SGLT2i. HbA1c, BW, mass index (BMI), blood pressure (BP) hypopnea (AHI) were before after administration. relationships between reduction AHI other variables examined using Pearson correlation analysis. have got result that reduced from 31.9 ± 18.0 18.8 11.5 events per hr (p = 0.003). BW BMI decreased significantly, whereas BP did not. analysis showed significant relationship pre-administration AHI. In conclusion, not only but also significantly has potential an effective treatment